Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

BACKGROUND. KIT has been suggested to be a potential therapeutic target for malignant melanoma. We evaluated the antitumor activity and safety of the KIT inhibitor nilotinib in metastatic melanoma patients harboring KIT gene mutations or amplifications. METHODS. We conducted a phase II multicenter t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Lee, Su Jin, Kim, Tae Min, Kim, Yu Jung, Jang, Kee-Taek, Lee, Hyo Jin, Lee, Soon Nam, Ahn, Mi Sun, Hwang, In Gyu, Lee, Suee, Lee, Moon-Hee, Lee, Jeeyun
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Melanoma and Cutaneous Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718426/
https://ncbi.nlm.nih.gov/pubmed/26424760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados